Effects of different preparations of oxprenolol on diurnal variations of non-steady-state exercise performance in patients with coronary heart disease evaluated by computer assisted ergospirometry.
The effect of two preparations of oxprenolol (80 mg twice a day; 160 mg slow-release once a day) on the diurnal non-steady-state exercise performance in patients with coronary heart disease (N = 11) has been studied after a treatment period of at least 7 days. 2 h after the intake of the standard preparation (80 mg oxprenolol) the symptom-limited exercise performance increased by 24%. The onset of symptoms of physical intolerance was postponed to work rates of heavier intensity (+18.8%). Despite a considerable fall in the exercise heart rate (-18.4%) the oxygen uptake per load was not affected suggesting that the adjustment of the cardio-pulmonary system to graded exercise was not impaired. As the reduction of the exercise heart rate is regarded as a distinct sign of beta-receptor blockade the standard regimen demonstrates a considerable long-term effect with respect to the heart rate regulation next morning (time interval 16 h). The slow-release preparation acts less powerfully in reducing the exercise heart rate in any test, but the beneficial effects on limiting symptoms of physical performance equal the standard regimen. The duration of the efficacy of slow-release oxprenolol is certainly limited: no effect on the exercise heart rate was demonstrable next morning (time interval 25 h). To improve the efficacy in symptomatic treatment of coronary heart disease the duration of effects of the drug and the physical activities of the individual during every day life should be taken into account to adjust the timing for intake.
D000328:Adult; D001682:Biological Availability; D002940:Circadian Rhythm; D003327:Coronary Disease / Q000503:physiopathology*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010096:Oxprenolol / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D010101:Oxygen Consumption / Q000187:drug effects; D005082:Physical Exertion; D012119:Respiration / Q000187:drug effects; D013147:Spirometry / Q000379:methods
D010096:Oxprenolol